share_log

Aegis Capital Initiates Coverage On Sunshine Biopharma With Buy Rating, Announces Price Target of $2.6

Aegis Capital Initiates Coverage On Sunshine Biopharma With Buy Rating, Announces Price Target of $2.6

Aegis Capital以買入評級啓動陽光生物製藥的保險,宣佈目標股價爲2.6美元
Benzinga ·  2023/08/07 12:02

Aegis Capital analyst David Bouchey initiates coverage on Sunshine Biopharma (NASDAQ:SBFM) with a Buy rating and announces Price Target of $2.6.

Aegis Capital分析師David Bouchey開始對陽光生物製藥(納斯達克股票代碼:SBFM)進行報道,評級爲買入,並宣佈目標股價爲2.6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論